Glutathione (injectable)

What it is

Glutathione (GSH) is a small tripeptide built from three amino acids — glutamate, cysteine, and glycine — joined by an unusual gamma peptide linkage that resists breakdown by peptidases S4. It is the most abundant non-protein thiol in animal cells and functions as an endogenous antioxidant, cycling between a reduced (GSH) and oxidized (GSSG) form to neutralize reactive oxygen species, peroxides, and heavy metals S4. This dossier concerns the compounded injectable, intravenous, and nebulized forms marketed as wellness products, which are distinct from oral glutathione sold as a food supplement in a separate track.

Marketed as

Injectable and IV glutathione is promoted primarily as a skin-lightening or "whitening" agent and as a general antioxidant or "detox" wellness infusion S2S3. Proposed skin-lightening mechanisms cited in the literature include inhibition of the melanin-producing enzyme tyrosinase and a shift from darker eumelanin toward lighter pheomelanin S3. These remain marketing and mechanistic claims rather than established clinical outcomes S3.

Regulatory status (US)

There is no FDA-approved injectable glutathione product for skin lightening or general wellness; the relevant FDA action treated it as an unapproved compounded use S1. In a June 2019 alert, the FDA reported that a glutathione powder used to compound sterile injectables was labeled "Caution: Dietary Supplement" and was only marketed for use in dietary supplements, not for pharmaceutical injection S1. FDA testing found bacterial endotoxin levels in the powder as high as five times the appropriate limit S1.

Around the world

Other national regulators have issued parallel warnings. The Philippine FDA's Advisory 2019-182 states that it has not approved any injectable product specifically for skin lightening, and notes glutathione's only approved injectable use there is as an adjunct in cisplatin chemotherapy S2. Saudi and other regional authorities have similarly cautioned the public against skin-whitening injections S2.

Evidence

Peer-reviewed reviews describe the evidence for injectable glutathione as weak. One review found only a single clinical trial of IV glutathione, with a small sample, a high dropout rate, and subjective assessment, and concluded there is little convincing evidence in favor of glutathione as a therapy for hyperpigmentation S3. A later narrative review likewise emphasized the need for higher-quality trials before clinical adoption S6.

Anti-doping

Glutathione is not listed as a named prohibited substance on the WADA Prohibited List S5. However, WADA prohibits intravenous infusions and injections of more than 100 mL per 12-hour period as a method, except for legitimate medical treatment, so the route of administration — not glutathione itself — is the relevant anti-doping consideration S5.

Safety

Regulators have documented serious adverse events associated with injectable glutathione. In the FDA case, patients who received IV glutathione experienced nausea, vomiting, lightheadedness, chills, and body aches within minutes, with one patient developing low blood pressure and breathing difficulty requiring hospitalization; endotoxin exposure can cause fever, chills, muscle pain, hypotension, shock, and death S1. Regulator advisories and reviews additionally cite toxic effects on the liver, kidneys, and nervous system, severe cutaneous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, and infection risks when administered in non-sterile settings S2S3.

What's changing

Marketing of glutathione injections and IV "drips" for cosmetic and wellness purposes has continued to grow, while the regulatory and evidence picture has not caught up: reviews through 2025 still call for higher-quality trials, and no US approval for these marketed uses exists S1S6. The gap between aggressive marketing and documented safety warnings remains the central issue for this compound S1S2.